{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:12Z","timestamp":1774343052932,"version":"3.50.1"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer\u2013BioNTech), and AZD1222 (AstraZeneca\u2013Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.<\/jats:p>","DOI":"10.3390\/microorganisms10030624","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:36:23Z","timestamp":1647401783000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-4640","authenticated-orcid":false,"given":"George","family":"Kroumpouzos","sequence":"first","affiliation":[{"name":"Department of Dermatology, Warren Alpert Medical School at Brown University, Providence, RI 02903, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-5862","authenticated-orcid":false,"given":"Maria Eleni","family":"Paroikaki","sequence":"additional","affiliation":[{"name":"Department of School of Medicine, Imperial College London, London SW7 2BX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Yumeen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Warren Alpert Medical School at Brown University, Providence, RI 02903, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Dermatology, R.D. Gardi Medical College, Ujjain 456010, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Catal\u00e0, A., Munoz-Santos, C., Galvan-Casas, C., Roncero Riesco, M., Revilla Nebreda, D., Sol\u00e1-Truyols, A., Giavedoni, P., Llamas-Velasco, M., Gonz\u00e1lez-Cruz, C., and Cubir\u00f3, X. (2021). Cutaneous reactions after SARS-CoV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. Br. J. Dermatol., epub ahead of print.","DOI":"10.1111\/bjd.20639"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","article-title":"Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines","volume":"157","author":"Robinson","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","unstructured":"(2022, January 17). JAMA Network Open\u2014Instructions for Authors: Ratings of the Quality of the Evidence. Available online: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/pages\/instructions-for-authors#SecRatingsofQuality."},{"key":"ref_6","unstructured":"(2022, January 17). The Centre for Evidence-Based Medicine. Available online: https:\/\/www.cebm.net."},{"key":"ref_7","first-page":"e425","article-title":"Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. \u2018COVID-arm\u2019: A clinical and histological characterization","volume":"35","author":"Hammerle","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.jaip.2021.07.012","article-title":"Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19","volume":"9","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jamadermatol.2021.1214","article-title":"Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: A case series","volume":"157","author":"Johnston","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/cid\/ciab518","article-title":"Incidence and characteristics of delayed injection site reaction to the mRNA-1273 SARS-CoV2 vaccine (Moderna) in a cohort of hospital employees","volume":"74","author":"Jacobson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.jaip.2021.03.055","article-title":"\u201cCOVID Arm\u201d: Very delayed large injection site reactions to mRNA COVID-19 vaccines","volume":"9","author":"Ramos","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40001-021-00557-z","article-title":"Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: A rare clinical reaction","volume":"26","author":"Hoff","year":"2021","journal-title":"Eur. J. Med. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdcr.2021.02.014","article-title":"\u201cCOVID arm\u201d: A reaction to the Moderna vaccine","volume":"10","author":"Wei","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1111\/all.14978","article-title":"Delayed local reactions after the first administration of the ChAdOx1 nCoV-19 vaccine","volume":"76","author":"Shin","year":"2021","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e15123","DOI":"10.1111\/dth.15123","article-title":"Cutaneous adverse effects and contraindications to COVID-19 vaccination; four cases and an illustrative review from an Asian country","volume":"34","author":"Choi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1111\/jdv.17633","article-title":"Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines","volume":"35","author":"Tihy","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team, and Food and Drug Administration (2021). Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14\u201323, 2020. Morb. Mortal. Wkly. Rep., 70, 46\u201351.","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2021.05.018","article-title":"Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients","volume":"14","author":"Sidlow","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2021.03.024","article-title":"Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines","volume":"127","author":"Kelso","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1111\/jdv.17575","article-title":"Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: A case series from the Philippines","volume":"35","author":"Yu","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1111\/jdv.17268","article-title":"Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: An Italian single-centre case series","volume":"35","author":"Corbeddu","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/dermatopathology8040049","article-title":"Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines","volume":"8","author":"Niebel","year":"2021","journal-title":"Dermatopathology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdcr.2021.07.038","article-title":"A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology","volume":"16","author":"Holmes","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team, and Food and Drug Administration (2021). Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine\u2014United States, December 21, 2020\u2013January 10, 2021. Morb. Mortal. Wkly. Rep., 70, 125\u2013129.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Peigottu, M.F., Ferreli, C., Atzori, M.G., and Atzori, L. (2021). Skin adverse reactions to novel messenger RNA Coronavirus vaccination: A case series. Diseases, 9.","DOI":"10.3390\/diseases9030058"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1111\/jdv.17578","article-title":"Rare cutaneous adverse effects of COVID-19 vaccines: A case series and review of the literature","volume":"35","author":"Annabi","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1111\/jdv.17248","article-title":"Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine","volume":"35","author":"Ackerman","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5070\/D3271052044","article-title":"Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine","volume":"27","author":"Jedlowski","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fathy, R.A., McMahon, D.E., Lee, C., Chamberlin, G.C., Rosenbach, M., Lipoff, J.B., Tyagi, A., Desai, S.R., French, L.E., and Lim, H.W. (2021). Varicella zoster and herpes simplex virus reactivation post-COVID-19 vaccination: A review of 40 cases in an international dermatology registry. J. Eur. Acad. Dermatol. Venereol., epub ahead of print.","DOI":"10.1111\/jdv.17646"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/jocd.14210","article-title":"20 post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media","volume":"20","author":"Lee","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Psichogiou, M., Samarkos, M., Mikos, N., and Hatzakis, A. (2021). Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines, 9.","DOI":"10.3390\/vaccines9060572"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.04.014","article-title":"Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases","volume":"12","author":"Chicharro","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/qjmed\/hcab208","article-title":"Herpes zoster following COVID-19 vaccine: A report of three cases","volume":"114","author":"Chiu","year":"2021","journal-title":"QJM Int. J. Med."},{"key":"ref_36","first-page":"e750","article-title":"Herpes zoster following SARS-CoV-2 vaccination\u2014A series of four cases","volume":"35","author":"Filipe","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijid.2021.08.048","article-title":"Herpes zoster after COVID vaccination","volume":"111","author":"Lede","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00011-021-01491-w","article-title":"A case of reactivation of varicella-zoster virus after BNT162b2 vaccine second dose?","volume":"70","author":"Santovito","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.36849\/JDD.6146","article-title":"Herpes zoster following COVID-19 vaccination","volume":"20","author":"David","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1111\/jocd.14372","article-title":"Pityriasis rosea following SARS-CoV-2 vaccination: A case series","volume":"20","author":"Temiz","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1111\/jdv.17342","article-title":"Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine","volume":"35","author":"Cyrenne","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1080\/21645515.2021.1963173","article-title":"Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine","volume":"17","author":"Cohen","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e15040","DOI":"10.1111\/dth.15040","article-title":"Post COVID-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male","volume":"34","author":"Adya","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_44","first-page":"431","article-title":"Pityriasis rosea as a possible complication of vaccination against COVID-19","volume":"118","author":"Dormann","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_45","first-page":"e489","article-title":"Pityriasis rosea, COVID-19 and vaccination: New keys to understand an old acquaintance","volume":"35","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","first-page":"e34","article-title":"Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination","volume":"185","author":"Morgado","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"752443","DOI":"10.3389\/fmed.2021.752443","article-title":"Case report: Pityriasis rosea-like eruption following COVID-19 vaccination","volume":"8","author":"Leerunyakul","year":"2021","journal-title":"Front. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/ijd.15700","article-title":"Pityriasis rosea after mRNA COVID-19 vaccination","volume":"60","author":"Abdullah","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bostan, E., and Jarbou, A. (2021). Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J. Med. Virol., epub ahead of print.","DOI":"10.1002\/jmv.27364"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Larson, V., Seidenberg, R., Caplan, A., Brinster, N.K., Meehan, S.A., and Kim, R.H. (2021). Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J. Cutan. Pathol., epub ahead of print.","DOI":"10.1111\/cup.14104"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1111\/jdv.17340","article-title":"Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: Another piece of SARS-CoV-2 skin puzzle?","volume":"35","author":"Mazzatenta","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjd.20404","article-title":"Pernio after COVID-19 vaccination","volume":"185","author":"Lopez","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2021.03.046","article-title":"New-onset chilblains in close temporal association to mRNA-1273 (Moderna) vaccination","volume":"12","author":"Kha","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Qiao, J.W., Dan, Y., Wolf, M.E., Zoccoli, C.M., Demetriou, T.J., and Lennon, R.P. (2021). Post-vaccination COVID toes (chilblains) exacerbated by rituximab infusion suggests interferon activation as mechanism. Mil. Med., epub ahead of print.","DOI":"10.1093\/milmed\/usab314"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cazzato, G., Romita, P., Foti, C., Cimmino, A., Colagrande, A., Arezzo, F., Sablone, S., Barile, A., Lettini, T., and Resta, L. (2021). Purpuric skin rash in a patient undergoing Pfizer-BioNTech COVID-19 vaccination: Histological evaluation and perspectives. Vaccines, 9.","DOI":"10.3390\/vaccines9070760"},{"key":"ref_56","first-page":"e16858","article-title":"Petechiae and desquamation of fingers following immunization with BTN162b2 messenger RNA (mRNA) COVID-19 vaccine","volume":"13","author":"Irvine","year":"2021","journal-title":"Cureus"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-021-02190-6","article-title":"COVID-19\/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: A challenging clinical conundrum in diagnosis and treatment","volume":"314","author":"Munavalli","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdcr.2021.02.018","article-title":"Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation","volume":"10","author":"Munavalli","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/jocd.14312","article-title":"Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination\u2014A case report","volume":"20","author":"Michon","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Coto-Segura, P., Fern\u00e1ndez-Prada, M., Mir-Bonaf\u00e9, M., Garc\u00eda-Garc\u00eda, B., Gonz\u00e1lez-Iglesias, I., Alonso-Penanes, P., Gonz\u00e1lez-Guerrero, M., Guti\u00e9rrez-Palacios, A., Miranda-Mart\u00ednez, E., and Martin\u00f3n-Torres, F. (2021). Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: Report of four cases and review of the literature. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14835"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1111\/jdv.17494","article-title":"Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine","volume":"35","author":"Leasure","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1111\/jdv.17225","article-title":"Prompt onset of Rowell\u2019s syndrome following the first BNT162b2 SARS-CoV-2 vaccination","volume":"35","author":"Gambichler","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ced.14714","article-title":"A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine","volume":"46","author":"Lavery","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ijrobp.2021.02.048","article-title":"COVID-19 Vaccine-induced radiation recall phenomenon","volume":"110","author":"Soyfer","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lim, P.N., and Wylie, G. (2021). Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14898"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Dash, S., Sirka, C.S., Mishra, S., and Viswan, P. (2021). COVID-19 vaccine induced Steven-Johnson syndrome: A case report. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14784"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.oooo.2021.06.019","article-title":"Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: A case report","volume":"132","author":"Elboraey","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_68","first-page":"e17215","article-title":"Toxic epidermal necrolysis post COVID-19 vaccination\u2014First reported case","volume":"13","author":"Bakir","year":"2021","journal-title":"Cureus"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Majid, I., and Mearaj, S. (2021). Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female. Dermatol. Ther., epub ahead of print.","DOI":"10.1111\/dth.15146"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e243173","DOI":"10.1136\/bcr-2021-243173","article-title":"Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine","volume":"14","author":"Martin","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e04865","DOI":"10.1002\/ccr3.4865","article-title":"New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination","volume":"9","author":"Kaminetsky","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e15141","DOI":"10.1111\/dth.15141","article-title":"Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant)","volume":"34","author":"Sandhu","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"M\u00fccke, V.T., Knop, V., M\u00fccke, M.M., Ochsendorf, F., and Zeuzem, S. (2021). First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: A case report. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06655-x"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hunjan, M.K., Roberts, C., Karim, S., and Hague, J. (2021). Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14878"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2021.2474","article-title":"Association of facial pustular neutrophilic eruption with messenger RNA-1273 SARS-CoV-2 vaccine","volume":"157","author":"Merrill","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_76","first-page":"e14453","article-title":"BCG scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in two international healthcare workers","volume":"13","year":"2021","journal-title":"Cureus"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bostan, E., Elmas, L., Yel, B., and Yalici-Armagan, B. (2021). Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases. Dermatol. Ther., epub ahead of print.","DOI":"10.1111\/dth.15110"},{"key":"ref_78","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2021.08.035","article-title":"Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine","volume":"17","author":"Perna","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1111\/jdv.17561","article-title":"New onset of mainly guttate psoriasis after COVID-19 vaccination: A case report","volume":"35","author":"Lehmann","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1111\/jdv.17502","article-title":"New onset of remitting seronegative symmetrical synovitis with. pitting oedema and palmoplantar psoriasis flare-up after SARS-CoV-2 vaccination","volume":"35","author":"Quattrini","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e15114","DOI":"10.1111\/dth.15114","article-title":"Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine","volume":"34","author":"Joseph","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000517256","article-title":"Darier\u2019s disease flare following COVID-19 vaccine","volume":"13","author":"Elbaek","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/jdv.17221","article-title":"Lichen planus arising after COVID-19 vaccination","volume":"35","author":"Hiltun","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdermsci.2021.06.006","article-title":"Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations","volume":"103","author":"Ohsawa","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Afacan, E., Ogut, B., Ustun, P., \u015eent\u00fcrk, E., Yaz\u0131c\u0131, O., and Ad\u0131\u015fen, E. (2021). Radiation recall dermatitis triggered by inactivated COVID-19 vaccine. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14786"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Mungmunpuntipantip, R., and Wiwanitkit, V. (2021). COVID-19 vaccination and exanthema like eruption. Clin. Exp. Dermatol., epub ahead of print.","DOI":"10.1111\/ced.14908"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"McMahon, D.E., Kovarik, C.L., Damsky, W., Rosenbach, M., Lipoff, J.B., Tyagi, A., Chamberlin, G., Fathy, R., Nazarian, R.M., and Desai, S.R. (2021). Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. J. Am. Acad. Dermatol., epub ahead of print.","DOI":"10.1016\/j.jaad.2021.09.002"},{"key":"ref_90","unstructured":"(2021, November 07). ASDS Provides Guidance Regarding SARS-CoV-2 mRNA Vaccine Side Effects. 28 December 2020. Available online: https:\/\/www.prweb.com\/releases\/asds_provides_guidance_regarding_sars_cov_2_mrna_vaccine_side_effects_in_dermal_filler_patients\/prweb17636524.htm."},{"key":"ref_91","unstructured":"United States Census Bureau (2021, November 15). Your Health Care Is in Women\u2019s Hands, Available online: https:\/\/www.census.gov\/library\/stories\/2019\/08\/your-health-care-in-womens-hands.html."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e12044","DOI":"10.1002\/clt2.12044","article-title":"Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up","volume":"11","author":"Rasmussen","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/ALX02225E","article-title":"Practical recommendations for the allergological risk assessment of the COVID-19 vaccination\u2014A harmonized statement of allergy centers in Germany","volume":"5","author":"Worm","year":"2021","journal-title":"Allergol. Sel."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lim, R.K., Kalagara, S., Chen, K.K., Mylonakis, E., and Kroumpouzos, G. (2021). Dermatology in a multidisciplinary approach with infectious disease and obstetric medicine against COVID-19. Int. J. Womens Dermatol., epub ahead of print.","DOI":"10.1016\/j.ijwd.2021.08.008"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/3\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:53Z","timestamp":1760135813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/3\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["microorganisms10030624"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms10030624","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}